secwatch.observer — SEC 8-K summary
======================================

Issuer:     Whitehawk Therapeutics, Inc. (WHWK)
CIK:        0001422142
Form:       8-K
Filed at:   2024-08-07T23:59:59+00:00
Accession:  0001628280-24-035390
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aadi Bioscience Q2 FYARRO sales $6.2M, net loss $14.6M; PRECISION1 interim analysis Q3
--------------------------------------------------------------------------------

- FYARRO net product sales $6.2M for Q2 2024, up 15% quarter-over-quarter, flat YoY.
- Net loss of $14.6M vs. $18.0M in Q2 2023; cash and investments $78.6M as of June 30, 2024.
- Two-thirds interim analysis of fully enrolled PRECISION1 trial expected in Q3 2024.
- Enrollment ongoing in Phase 2 trials for endometrial cancer and neuroendocrine tumors.
- Cash runway expected to fund operations into Q4 2025 based on current plans.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422142/000162828024035390/0001628280-24-035390-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422142/000162828024035390/aadi-20240807.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-035390

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer